News Releases

Brussels - 30 November 2012 – Today NYSE Liffe, the Europe-based derivatives business of NYSE Euronext (NYX), added options on the shares of ThromboGenics, a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, to its highly successful range of equity option classes. The options are available on the Brussels derivatives market of NYSE Liffe.

Vincent Van Dessel, CEO of NYSE Euronext Brussels commented: “We are pleased to announce the listing of options on ThromboGenics, a successful Belgian company and a great example of our leading role in the biotech industry niche. This listing will further enhance the visibility of the company.”

Ade Cordell, Executive Director, Head of Equity Derivatives added: “ We are delighted with the listing of this new option class on our Brussels market. With the addition of the ThromboGenics option class to our scope of existing contracts; we now have 278 single stock options listed on our central order books offering our market participants a highly diversified set of derivatives for their investment needs.”

Chris Buyse, CFO of  ThromboGenics, commented: “We are pleased with the listing of options on the shares of our company. We believe that this will offer our shareholders an alternative financial instrument on the NYSE Liffe market. This will enhance the liquidity of our share and increase the visibility of ThromboGenics in the financial world.”

These American-style options will expire on the third Friday of the expiry month and will have initial lifetimes of one to six months. Options on ThromboGenics are introduced under trading symbol THR.

Each option represents 100 shares in ThromboGenics and will be centrally cleared via LCH.Clearnet SA. Liquidity in the options will be supported by 2 market makers: All Options International B.V. and B&Btrading NV. NYSE Liffe lists stock options (also known as individual equity options) on 278 leading European companies via the Amsterdam, Brussels, London and Paris central order books.

The introduction of the new option class on ThromboGenics is the first one on a Belgian biotech company. ThromboGenics is an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines. The Company’s lead product, JETREA® (ocriplasmin), has been approved by the US FDA for the treatment of symptomatic VMA. The US launch is planned from mid January 2013. In March 2012, ThromboGenics signed a strategic partnership with Alcon (Novartis) for the commercialization of ocriplasmin outside the United States. The JETREA® European Marketing Authorisation Application is currently under review by the European Medicines Agency. A decision on European approval is expected in the first half of 2013. 

To mark today’s special occasion, Chris Buyse, CFO of ThromboGenics, rang the opening bell which denotes the opening of NYSE Euronext's European market, together with Vincent Van Dessel, CEO of NYSE Euronext Brussels.

Information

NYSE Euronext
Jean-Yves Daxhelet
Tel.: +32 2 761 66 93
E-mail : jean-yves.daxhelet@interel.be

ThromboGenics
Wouter Piepers, Global Head of Corporate Communications
Tel.: +32 16 75 13 10 / +32 478 33 56 32
E-mail: wouter.piepers@thrombogenics.com

About NYSE Euronext
NYSE Euronext (NYX) is a leading global operator of financial markets and provider of innovative trading technologies. The company's exchanges in Europe and the United States trade equities, futures, options, fixed-income and exchange-traded products. With approximately 8,000 listed issues (excluding European Structured Products), NYSE Euronext's equities markets - the New York Stock Exchange, NYSE Euronext, NYSE MKT, NYSE Alternext and NYSE Arca - represent one-third of the world’s equities trading, the most liquidity of any global exchange group. NYSE Euronext also operates NYSE Liffe, one of the leading European derivatives businesses and the world's second-largest derivatives business by value of trading. The company offers comprehensive commercial technology, connectivity and market data products and services through NYSE Technologies. NYSE Euronext is in the S&P 500 index. For more information, please visit: http://www.nyx.com.

About ThromboGenics
ThromboGenics is an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines. The Company’s lead product, JETREA® (ocriplasmin), has been approved by the FDA for the treatment of symptomatic VMA. The Marketing Authorisation Application (MAA) for ocriplasmin is under review in Europe.

In March 2012, ThromboGenics signed a strategic partnership with Alcon (Novartis) for the commercialization of JETREA® outside the United States. Under this agreement, ThromboGenics could receive up to a total of €375 million in up-front and milestone payments. It will receive significant royalties from Alcon’s net sales of JETREA®. ThromboGenics and Alcon intend to share the costs equally of developing JETREA® for a number of new vitreoretinal indications.

ThromboGenics is also further exploring anti-PIGF (Placental Growth Factor), formerly referred to as TB-403, for the treatment of ophthalmic indications.

ThromboGenics is headquartered in Leuven, Belgium, and has-offices in Iselin, NJ (US) and Dublin, Ireland. The Company is listed on the NYSE Euronext Brussels exchange under the symbol THR. More information is available at www.thrombogenics.com.

Disclaimer
None of the information contained in this press release constitutes an offer, solicitation or recommendation to acquire or dispose of any security or investment or to engage in any other transaction or to provide legal, tax, accounting or investment advice or services regarding the suitability or profitability of any security or investment.

The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by NYSE Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. NYSE Euronext encourages you to reach your own opinion as to whether investments are appropriate or relevant and recommends you not to make any decisions on the basis of the information contained in this publication before checking it, as you will bear full responsibility for any use that you make of it. Persons wishing to trade products available on NYSE Euronext markets or wishing to offer such products to third parties (whether by way of admission to listing and/or trading of products, or otherwise) are advised, before doing so, to check their legal and regulatory position in the relevant territory and to understand the related risks.

NYSE Euronext has not made any recommendations regarding the merit of any company, security or other financial product or investment identified in the presentation, made any recommendation regarding the purchase or sale of any such company, security, financial product or investment, or endorsed or sponsored any company identified in the presentation. This press release is not intended to be, and shall not constitute in any way a binding or legal agreement, or impose any legal obligation or duty on NYSE Euronext or any of its affiliates.

This press release speaks only as of this date. NYSE Euronext disclaims any duty to update the information herein.

NYSE Euronext refers to NYSE Euronext and its affiliates and references to NYSE Euronext in this publication include each and any such company as the context dictates. NYSE Euronext, New York Stock Exchange, NYSE Amex, NYSE Alternext, NYSE Arca and NYSE Liffe are registered marks of NYSE Euronext. © 2012, NYSE Euronext – All rights reserved.